Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy

Lisbell D. Estrada, Cristian Lasagna Reeves, Claudio Soto

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide (Refolo & Fillit, 2004), is the most common cause of dementia in the elderly. By 2050, the number of people with AD is expected to triple, placing an enormous burden on the health care and social care systems. This neurodegenerative disorder is characterized clinically by progressive loss of memory, language problems, social withdrawal, and deterioration of executive functions, and eventually culminates in death (Citron, 2002). Most AD cases are sporadic, with multiple risk factors, such as aging, environmental stress, and diet. The remaining AD cases, which account for 5- 10% of total AD cases, are inherited from one generation to the next and are referred to as familial AD (FAD).

Original languageEnglish (US)
Title of host publicationPharmacological Mechanisms in Alzheimer's Therapeutics
PublisherSpringer New York
Pages238-254
Number of pages17
ISBN (Electronic)9780387715223
ISBN (Print)9780387715216
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Therapeutics
Social Problems
Executive Function
Memory Disorders
Neurodegenerative Diseases
Dementia
Language
Diet
Delivery of Health Care

Keywords

  • Alzheimer's disease
  • amyloid
  • therapy
  • β-sheet breakers

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Estrada, L. D., Lasagna Reeves, C., & Soto, C. (2007). Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. In Pharmacological Mechanisms in Alzheimer's Therapeutics (pp. 238-254). Springer New York. https://doi.org/10.1007/978-0-387-71522-3_15

Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. / Estrada, Lisbell D.; Lasagna Reeves, Cristian; Soto, Claudio.

Pharmacological Mechanisms in Alzheimer's Therapeutics. Springer New York, 2007. p. 238-254.

Research output: Chapter in Book/Report/Conference proceedingChapter

Estrada, LD, Lasagna Reeves, C & Soto, C 2007, Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. in Pharmacological Mechanisms in Alzheimer's Therapeutics. Springer New York, pp. 238-254. https://doi.org/10.1007/978-0-387-71522-3_15
Estrada LD, Lasagna Reeves C, Soto C. Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. In Pharmacological Mechanisms in Alzheimer's Therapeutics. Springer New York. 2007. p. 238-254 https://doi.org/10.1007/978-0-387-71522-3_15
Estrada, Lisbell D. ; Lasagna Reeves, Cristian ; Soto, Claudio. / Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. Pharmacological Mechanisms in Alzheimer's Therapeutics. Springer New York, 2007. pp. 238-254
@inbook{23ed4f359a1e4f4b9137b1711c6e5db6,
title = "Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy",
abstract = "Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide (Refolo & Fillit, 2004), is the most common cause of dementia in the elderly. By 2050, the number of people with AD is expected to triple, placing an enormous burden on the health care and social care systems. This neurodegenerative disorder is characterized clinically by progressive loss of memory, language problems, social withdrawal, and deterioration of executive functions, and eventually culminates in death (Citron, 2002). Most AD cases are sporadic, with multiple risk factors, such as aging, environmental stress, and diet. The remaining AD cases, which account for 5- 10{\%} of total AD cases, are inherited from one generation to the next and are referred to as familial AD (FAD).",
keywords = "Alzheimer's disease, amyloid, therapy, β-sheet breakers",
author = "Estrada, {Lisbell D.} and {Lasagna Reeves}, Cristian and Claudio Soto",
year = "2007",
doi = "10.1007/978-0-387-71522-3_15",
language = "English (US)",
isbn = "9780387715216",
pages = "238--254",
booktitle = "Pharmacological Mechanisms in Alzheimer's Therapeutics",
publisher = "Springer New York",

}

TY - CHAP

T1 - Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy

AU - Estrada, Lisbell D.

AU - Lasagna Reeves, Cristian

AU - Soto, Claudio

PY - 2007

Y1 - 2007

N2 - Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide (Refolo & Fillit, 2004), is the most common cause of dementia in the elderly. By 2050, the number of people with AD is expected to triple, placing an enormous burden on the health care and social care systems. This neurodegenerative disorder is characterized clinically by progressive loss of memory, language problems, social withdrawal, and deterioration of executive functions, and eventually culminates in death (Citron, 2002). Most AD cases are sporadic, with multiple risk factors, such as aging, environmental stress, and diet. The remaining AD cases, which account for 5- 10% of total AD cases, are inherited from one generation to the next and are referred to as familial AD (FAD).

AB - Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide (Refolo & Fillit, 2004), is the most common cause of dementia in the elderly. By 2050, the number of people with AD is expected to triple, placing an enormous burden on the health care and social care systems. This neurodegenerative disorder is characterized clinically by progressive loss of memory, language problems, social withdrawal, and deterioration of executive functions, and eventually culminates in death (Citron, 2002). Most AD cases are sporadic, with multiple risk factors, such as aging, environmental stress, and diet. The remaining AD cases, which account for 5- 10% of total AD cases, are inherited from one generation to the next and are referred to as familial AD (FAD).

KW - Alzheimer's disease

KW - amyloid

KW - therapy

KW - β-sheet breakers

UR - http://www.scopus.com/inward/record.url?scp=67650892608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650892608&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-71522-3_15

DO - 10.1007/978-0-387-71522-3_15

M3 - Chapter

SN - 9780387715216

SP - 238

EP - 254

BT - Pharmacological Mechanisms in Alzheimer's Therapeutics

PB - Springer New York

ER -